REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to beat back tough blood cancers
Disease control Recruiting nowThis study tests a mix of six chemotherapy drugs in people whose acute lymphoblastic leukemia, lymphoblastic lymphoma, or related blood cancers have returned or stopped responding to treatment. The goal is to see if this combination can shrink or control the cancer and to check f…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New combo tackles resistant leukemia in phase 2 trial
Disease control Recruiting nowThis study tests a combination of two drugs—blinatumomab and ponatinib—along with chemotherapy in adults with a specific type of leukemia (Ph-positive ALL) that has come back or not responded to prior treatment. The goal is to see if this approach can improve response rates and s…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New CAR t therapy trial aims to outsmart tough leukemia in kids
Disease control Recruiting nowThis study tests a special cell therapy called CAR T for children and young adults with a type of leukemia that has come back or not responded to treatment. Doctors will collect immune cells from the patient, modify them to attack cancer cells, and give them back after chemothera…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
Engineered immune cells take on relapsed leukemia in new trial
Disease control Recruiting nowThis study tests a treatment called CAR T cell therapy for adults with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has returned or not responded to standard treatments. The therapy involves taking a patient's own immune cells, modifying them in a lab to bett…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and at…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
Radioactive antibody targets leukemia before transplant
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-phase trial tests a new type of CAR T-cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target three cancer marker…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study tests an oral drug called ONC201 in adults whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink or control the cancer. About 120 pa…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Engineered immune cells take on deadly T-Cell cancers in new trial
Disease control Recruiting nowThis study tests a new treatment called CD5 CAR T cells for people with T-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells or cells from a donor, which are modified in a lab to better attack the cancer. The tri…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
Engineered immune cells take on tough leukemia
Disease control Recruiting nowThis early-phase trial tests a new type of CAR T cell therapy for people with acute lymphoblastic leukemia (ALL) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better target and kill cancer cells by …
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Recruiting nowThis study tests a new treatment called CD5-CAR T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells, modified to target and kill cancer cells. The trial will first fi…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Radioactive antibody blasts cancer before stem cell rescue in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Immune boosting cells show promise in fighting blood cancers after transplant
Disease control Recruiting nowThis study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple mye…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC